Urology
Bladder Cancer Pathway (2WW)
Painless visible haematuria → 2WW; cystoscopy + CT urogram; TURBT + intravesical / cystectomy.
Source: NICE NG12; BAUS
Step 1 of ~3
info
Refer 2WW
NICE NG12 (2WW):
• Aged ≥45 with unexplained visible haematuria without UTI OR persistent / recurrent visible haematuria after UTI.
• Aged ≥60 with unexplained non-visible haematuria + dysuria OR raised WBC.
Risk: smoking (4×), aromatic amines (rubber, dye, leather, painting), chronic catheter, cyclophosphamide, schistosomiasis.
Workup: cystoscopy + CT urogram (CTU). Urine cytology.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Methylene Blue · Guanylate Cyclase / Nitric Oxide Pathway Inhibitor
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Sodium phenylbutyrate · Ammonia scavenger (alternative pathway)
- Mirabegron (Overactive Bladder — Elderly) · Beta-3 Adrenoceptor Agonist
- Marstacimab · Anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody
Decision support only. Always apply local guidelines and clinical judgement.